Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review
Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review
复制标题
DOI：
10.1080/17474124.2022.2020643
复制
发表时间：
2021-12
影响因子：
3.9
通讯作者：
Yifan Wang;J. Yi;Xiaowei Liu
中科院分区：
文献类型：
--
作者：
Yifan Wang;J. Yi;Xiaowei Liu
摘要前言胰腺癌是一种发病率高、预后差的恶性肿瘤。其极差的预后通常归因于其早期侵袭和转移以及化疗耐药的存在，这可能与癌症干细胞（CSCs）的潜在作用有关。双皮质素样激酶1（Dclk1）是前列腺癌中肿瘤干细胞的标志物，与肿瘤的发生、转移及预后密切相关。覆盖的领域一个审查服务于提供一个全面的概述Dclk1在PC的发病机制，诊断，预后和治疗。专家意见寻找潜在的关键生物标志物PC已成为一个迫切需要解决的问题。Dclk 1在PC中的表达增加，其作用与突变的Kras有关，支持其可能是潜在的新靶点。因此，Dclk1有望成为未来临床应用的候选生物标志物和治疗靶点。
ABSTRACT Introduction Pancreatic cancer (PC) is a malignant tumor with significantly increased incidence and poor prognosis. Its extremely poor prognosis is generally attributed to its early invasion and metastasis as well as the presence of chemotherapy resistance, which may be related to the potential role of cancer stem cells (CSCs). Doublecortin-like kinase 1 (Dclk1) has been recognized to be a marker of CSCs in PC, showing intimate association with its occurrence, metastasis, and poor prognosis. Areas covered A review serves to provide a comprehensive overview of Dclk1 in the pathogenesis, diagnosis, prognosis, and treatment in PC. Expert opinion Searching for potential key biomarkers for PC has been an urgent issue to be addressed. The expression of Dclk1 is increasing in PC, and its effect is linked to the mutant Kras, supporting that it may be a potential new target. Therefore, it highlights Dclk1 as a candidate biomarker and therapeutic target in future clinical application.